Evidence map›Paper›PMID 32381085›Full record

ArticleBMC endocrine disorders2020

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin.

Hiroyuki Uchinuma, Masashi Ichijo, Noriyuki Harima, Kyoichiro Tsuchiya

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Glucocorticoid-Induced Hyperglycemia: A Neglected Problem.Endocrinology and metabolism (Seoul, Korea) · 2024
    Review
  4. Article
  5. Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter].Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hiroyuki UchinumaDepartment of Diabetes and Endocrinology, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Masashi IchijoDepartment of Diabetes and Endocrinology, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Noriyuki HarimaDepartment of Diabetes and Endocrinology, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan.
Kyoichiro TsuchiyaDepartment of Diabetes and Endocrinology, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 4093898, Japan. tsuchiyak@yamanashi.ac.jp.ORCID http://orcid.org/0000-0001-9829-1018
University of Yamanashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucocorticoid (GC)-induced hyperglycemia is characterized by elevated postprandial blood glucose, which commonly requires multiple insulin injections. We investigated whether a long-acting glucagon-like peptide-1 receptor agonist, dulaglutide (Dula), safely improved GC-induced hyperglycemia in inpatients, to reduce insulin injection frequency.

methodsThe data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated. Baseline data were collected at the beginning of GC treatment. The primary outcome in this study was glycemic control, which was compared between the groups using the six-point blood glucose (before and 2 h after each meal) profiles at discharge. The daily injection frequency of injectable drugs at discharge were also compared between groups.

resultsNo specific trend of underlying diseases was observed between the non-Dula and Dula groups. The proportion of patients previously administered with GC pulse therapy was comparable between the two groups. No significant differences were observed between groups, in the starting maintenance GC dose, GC dose at pretreatment of Dula and discharge, and cumulative GC dose during the observation. Six-point blood glucose levels at pretreatment and discharge were comparable between the two groups. However, daily injection frequency of injectable drugs and insulin dose were significantly lower in the Dula group than that in the non-Dula group. No differences were observed in the number of hypoglycemic events, the elevation of serum pancreatic enzyme levels, or gastrointestinal adverse events.

conclusionThese findings suggest that Dula could provide glycemic control while reducing the insulin dose and injection frequency in inpatients with GC-induced hyperglycemia. The occurrence of adverse events such as gastrointestinal symptoms and hypoglycemia did not increase in the Dula-treated patients compared to those not treated, suggesting its safety.

Indexed as

AgedAged, 80 and overBlood GlucoseDrug Administration ScheduleFemaleGlucagon-Like PeptidesGlucocorticoidsHospitalizationHumansHyperglycemiaHypoglycemic AgentsImmunoglobulin Fc FragmentsInsulinMaleMiddle AgedRecombinant Fusion ProteinsBlood GlucosedulaglutideGlucagon-Like PeptidesGlucocorticoidsHypoglycemic AgentsImmunoglobulin Fc FragmentsInsulinRecombinant Fusion ProteinsDiabetes mellitusDulaglutideGlucocorticoid-induced hyperglycemiaInsulin

Identifiers

PMID32381085
PMCPMC7203793
OpenAlexW3023693788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.